<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709628</url>
  </required_header>
  <id_info>
    <org_study_id>Enterome</org_study_id>
    <nct_id>NCT03709628</nct_id>
  </id_info>
  <brief_title>A Study of a FimH Blocker, EB8018, in Crohn's Disease Patients</brief_title>
  <acronym>EBFIM117</acronym>
  <official_title>An Open-label, Multicenter, Pharmacokinetic Study of a FimH Blocker, EB8018, in Crohn's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enterome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Enterome</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Enterome small molecule drug EB8018 is a first-in-class FimH blocker to be studied in Crohn's
      disease patients. The proposed indication for EB8018, as an add-on therapy, will be the
      treatment of adult patients suffering from Crohn's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, multicenter study will enroll 8 evaluable patients with active Crohn's
      disease and will consist of 2 parts. Part 1 will include 2 sentinel patients with a single
      dosing period followed by a 13-day multiple dosing period. Part 2 will include the 6
      remaining patients with multiple dosing only. This Phase 1b study will investigate the PK,
      safety, preliminary effects of the gut microbiome, and inflammatory biomarkers of EB8018
      following 13 days of consecutive BID oral dosing in patients with Crohn's disease.

      Part 1 of this study will demonstrate a single oral dose of EB8018 that is safe and tolerable
      in patients with Crohn's disease and Part 2 of this study will characterize the PK profile
      when administered as multiple oral doses.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 7, 2018</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multicenter, open-label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day1, Day13</time_frame>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day1</time_frame>
    <description>Time to maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24</measure>
    <time_frame>Day1; Day13</time_frame>
    <description>Area under the plasma concentration time curve from time 0 to 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2</measure>
    <time_frame>Day1; Day13</time_frame>
    <description>Terminal elimination half-life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>Up to Day22</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RR</measure>
    <time_frame>Up to Day22</time_frame>
    <description>Inter-Beat intervalle (sec)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QRS complex</measure>
    <time_frame>Up to Day22</time_frame>
    <description>intervalle (sec)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QT</measure>
    <time_frame>Up to Day22</time_frame>
    <description>duration (sec)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PR</measure>
    <time_frame>Up to Day22</time_frame>
    <description>intervalle (sec)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HR</measure>
    <time_frame>Up to Day22</time_frame>
    <description>Heart rate (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP</measure>
    <time_frame>Up to Day22</time_frame>
    <description>Blood pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RR</measure>
    <time_frame>Up to Day22</time_frame>
    <description>Respiratory rate (breaths per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temp</measure>
    <time_frame>Up to Day22</time_frame>
    <description>Temperature (C°)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Gut Microbiome</measure>
    <time_frame>Up to Day22</time_frame>
    <description>Overall gene richness and relative abundance of Bacteroidetes, Enterobacteriaceae, and Firmicutes from sequencing of stool samples.</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory Biomarkers</measure>
    <time_frame>Up to Day22</time_frame>
    <description>C-reactive protein</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory Biomarkers</measure>
    <time_frame>Up to Day22</time_frame>
    <description>Fecal calprotectin</description>
  </other_outcome>
  <other_outcome>
    <measure>CDAI score</measure>
    <time_frame>Up to Day22</time_frame>
    <description>CDAI calculation will be dependent on the parameters recorded in the subjects' diary and the parameters assessed at clinic visit by the investigator.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Patients with active Crohn's disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EB8018: 3000 mg for the single dose in Part 1 (2 sentinel patients) and 1500 mg BID for multiple dose administration over 13 days in Parts 1 and 2 (2 sentinel patients and 6 remaining patients), oral.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EB8018 (First-in-class FimH blocker)</intervention_name>
    <description>Drug: EB8018 EB8018 is an orally administered, first-in-class, FimH blocker
• In Part 1, a single oral dose of EB8018 3000 mg will be administered to the 2 sentinel patients in the morning on Day 1. In the multi-dose treatment period (part 1 and 2), multiple oral doses of EB8018 1500 mg will be administered to 2 + 6 patients BID (in the morning and evening) on Days 1 through 13.</description>
    <arm_group_label>Patients with active Crohn's disease</arm_group_label>
    <other_name>EB8018</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Selection Criteria:

          -  Male and female patients of nonchildbearing potential ≥18 years of age at screening
             and Day -1

          -  Active Crohn's disease based on an elevated calprotectin at baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Archet 2</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

